



COLGATE-PALMOLIVE (INDIA) LIMITED

Regd. Office :
Colgate Research Centre,
Main Street,
Hiranandani Gardens,
Powai,
Mumbai - 400 076.
Tel. : 67095050
Fax : (91 22) 25705088
www.colgatepalmolive.co.in
CIN : L24200MH1937PLC002700

April 06, 2019

The Secretary
BSE Limited
P.J. Towers- 25th floor
Dalal Street
Mumbai- 400001

Scrip Code: 500830

The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block – G
Bandra – Kurla Complex
Bandra (East), Mumbai 400 051

Symbol: COLPAL
Series: EQ

Dear Sir,

Re: Clarification on the news article.

This has reference to your query dated April 5, 2019 seeking clarification on the newspaper article published in Hindustan Times titled “Maharashtra FDA notice for Colgate brand, Sensodyne for misleading consumers”.

In this regard, we wish to clarify that the Maharashtra FDA’s recent action pertains to only one specific variant of Toothpaste “Colgate Sensitive” which is known to provide benefit to sensitive teeth. The aforesaid action of Maharashtra FDA only pertains to their view that certain benefits mentioned on the pack cause the product to fall under a drug license. The quality and benefits of Colgate Sensitive Toothpaste are not at issue.

Colgate Sensitive Toothpaste provides everyday oral health benefits and is recognized for the scientifically-proven relief it provides to consumers having sensitive teeth. It is manufactured in India under a valid license issued by the competent FDA authority and complies with all statutory FDA quality requirements as set by The Bureau of Indian Standards (BIS). We have provided Maharashtra FDA with details of our valid license, claim support and other information. We are cooperating fully and working with the FDA to resolve their queries.

We now proceed to respond to the queries raised by you as under:

- a) Whether such event stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order.

The samples were picked up by Thane Office of Maharashtra FDA on 5th September, 2018 and sent for analysis. The analysis report came on 27th February, 2019 which confirms that the product complies with the quality and standards prescribed by the BIS. However, the products blocked during sample pick-up (38663 packs worth Rs. 4186006/-) were seized for certain claims which according to Maharashtra FDA fall under Drug License. The said quantity and value does not qualify to be material.

b) The material impact of this article on the Company.

There is no material impact of this Article on the Company.

c) Whether company are aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulations. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under Regulation 30 of the Listing Regulations.

To the best of our knowledge, the Company is not aware of any information that has not been announced to the Exchanges under Regulation 30 of Listing Regulation.

Please acknowledge receipt.

Thanking you,

Very truly yours

Colgate-Palmolive (India) Limited

A handwritten signature in blue ink, appearing to read 'K. Randhir Singh', is written over a horizontal line.

K. Randhir Singh

Company Secretary & Compliance Officer